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drugs indicated for influenza (24%) and viral infections (excluding HIV and hepa-
titis) (18%). ConClusions: From the analysis presented here, it is clear that there 
are striking differences between infectious and parasitic disease drug approvals in 
Japan and the USA. Given the concern in Japan over the emergence of new influenza 
strains with pandemic potential, this is a great focus, constituting approximately 
a quarter of all infectious and parasitic disease drugs for the PMDA compared to 
no submissions to the FDA.
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PoPulatIoN access to RotavIRus vaccINatIoN IN INdustRIalIzed 
couNtRIes: lessoNs leaRNt fRom cuRReNt exPeRIeNce
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objeCtives: In most European countries, there are usually four steps before popu-
lation access to a vaccination programme: vaccine marketing authorization by the 
European Commission, transposition of this agreement by national drug agencies, 
then recommendation and policy-decision steps on funding and implementation. 
During the recommendation step, specific to vaccines, health technology assess-
ment is often performed. Using rotavirus vaccination as an illustrative case, this 
study aims at better understanding the picture of population access, and identifying 
lessons learnt from current experience. Methods: An extensive systematic review 
of national universal rotavirus vaccination policies was conducted in 20 industrial-
ized countries (17 European & 3 major non-European). After key categories in vac-
cine evaluations were identified, comparative quantitative and qualitative analyses 
were conducted. Results: At mid-March 2014, out of the 20 countries considered, 13 
decided to include rotavirus vaccination in their childhood national vaccination pro-
gramme, 2 decided not to include it, while rotavirus decision-making process has not 
started or is underway in the remaining five countries. Published evaluations and/or 
advices on rotavirus vaccination were available in 16 countries. Quantitative analyses 
revealed that most of the countries did not take all categories into consideration, and 
some countries even assessed only two or three. ‘Burden of disease’ and ‘assessment 
of vaccine efficacy/safety’ were always taken into account, while ‘acceptability’ and 
‘implementation’ were less addressed. Qualitative analyses pointed out many differ-
ences in content and outcomes. ConClusions: Rotavirus vaccination policies across 
industrialised countries were found to be disparate, leading to unequal population 
access. Comparative analyses suggest there are different interpretations of the avail-
able evidence. This raises the need of a common decision integrated framework, using 
structured and systematic approach. This approach is not intended to substitute to 
authorities, but it could contribute to provide reproducible and structured interpreta-
tion of evidence, pave the way of the legitimacy of rotavirus vaccination programme.
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otHeR PublIc souRce of fuNd to maINtaIN QualIty aNd eQuIty
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objeCtives: This study is aiming at 1) tracking expenditure on HIVAIDS, 2)how 
the government contributed to one of the MDG priority programs in Indonesia 
and its sustainability for future financing since Indonesia is one country with 
growring number of new HIVAIDS infections. Methods: Cross sectional data from 
2006-2012 was used to capture spending for HIVAIDS interventions, followed by 
policy discussion. Results: Total spending for HIVAIDS interventions increased 
from USD 56,5 miilion in 2006 to USD 87 million in 2012. The government contri-
bution has slightly increased (26.6% in 2006 and 42.36% in 2012). We found that 
75% in 2011 and 70% in 2012 of the spending were related to health. Government 
contribution for HIVAIDS as compared to total health expenditure was very lim-
ited, amounted to 0,29%, 0,27% and 0,26% in 2009, 2010 and 2011 respectively. In 
contrast, for priority programs such as HIVAIDS, external partner contribution 
has been substantial. There has been a discussion to integrate financing to the 
publicly funded program such as universal coverage that has just started recently. 
Further analysis on Opportunitistic Infection and STDs service provision for most 
at risk population was done to assess potential inclusion to the benefit package. 
Separation of the cost components to balance the role of the government and 
other sources was also assessed. Unit cost of the STDs treatment is USD 24 exclud-
ing equipment and drug. However,other country’s experience showing that the 
interventions are integrated in the universal coverage using different scheme or 
top-up. ConClusions: It should be carefully assessed the integration of HIVAIDS 
treatment to the universal coverage scheme. Stigma reduction and different price 
for private clinics need to be explored to support quality and equity. To ensure 
sustainability of the program government should play a central role to maintain 
the program, involving NGOs to engage MARP and PLHIV.
NeuRologIcal dIsoRdeRs – clinical outcomes studies
PNd1
IvacaftoR foR PatIeNts wItH cystIc fIbRosIs: clINIcal effIcacy aNd 
cost-effectIveNess
Kostyuk A.1, Nurgozhin T.2, Akanov A.3
1Almaty State Instiitute for Continuing Medical Education, Astana, Kazakhstan, 2Nazarbayev 
University, The Center for Life Sciences, Astana, Kazakhstan, 3Astana Medical University, Astana, 
Kazakhstan
objeCtives: This review aims to appraise the clinical and cost effectiveness of 
ivacaftor for oral administration for the treatment of cystic fibrosis (CF) in patients 
age six years and elder who have at least one G551D mutation in the CFTR (cystic 
fibrosis transmembrane conductance regulator) gene. Methods: A limited litera-
ture search was conducted of key resources, and titles and abstracts of the retrieved 
publications were reviewed. Full-text publications were evaluated for final article 
selection according to predetermined criteria (population, intervention, comparator, 
patients were found to be 100.1± 27.9 and 109 ± 15.0 .Among males, difference 
was observed in mean of HRQOL between ADR patients (99±27.92) and non ADR 
patients(107.16±14.08). Same difference were observed in mean of HRQOL among 
females which was102.18±28.68 in ADR Patients and113.69±15.95 in ADR absent 
patients. ConClusions: There is a need for a greater awareness among the health 
care professionals, regarding prevention or minimization of occurrence of ADRs by 
more frequent interventions by physicians, thus improving medication adherence 
which leads to maximization of HRQOL in HIV patients.
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objeCtives: Multiple treatments are available for chronic hepatitis C virus (HCV) 
infection. Ethical, clinical, economic, and social barriers often prevent these patients 
from receiving the effective antiviral treatments now available. These barriers to 
care have received little attention in the literature, and yet, knowledge of the ethical 
and social justice aspects of HCV treatment can enhance the quality of care. This 
study systematically reviewed evidence on the social and lifestyle determinants of 
achieving viral eradication with antiviral therapy. Methods: A search of Medline, 
Embase, and Cochrane databases (between 2004 and January 2014) was conducted 
for primary articles/conference abstracts examining social and lifestyle factors. 
Analyzed the main ethical arguments are often presented to restrict patients’ access 
to HCV treatment: the balance of risk/benefit, justice, compliance, cost-effectiveness 
and discrimination. Results: Clinical and individual level barriers to HCV treat-
ment are well evidenced. These include patient and provider concerns regarding 
co-morbidities, adherence, and side effect management. Social factors affecting 
treatment access are less well evidenced. In attempting to map these, key barri-
ers fall into the following domains: social stigma, housing, criminalisation, health 
care systems, and gender. Key facilitating factors to treatment access include: 
combination intervention approaches encompassing social as well as biomedi-
cal interventions and integrated delivery of multidisciplinary care. No trial evalu-
ated effectiveness of treatment on long-term clinical outcomes. ConClusions: 
Successful treatment of HCV infection has undeniable long-term benefits with 
respect to reducing morbidity and mortality. Perhaps the most challenging issue 
is not whether there will be medical tools to effectively manage and treat HCV 
infection, but rather whether the economic resources and societal commitment 
will be adequate to embark on an ambitious agenda to eliminate this global public 
health problem. Combination intervention approaches need to encompass systemic 
changes in policy and health care delivery. Future research needs to better delineate 
social factors affecting treatment access.
INfectIoN – Health care use & Policy studies
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objeCtives: To analyze the relationship between the change of drug mix for 
Cephalosporins and their cost increases in order to provide a reference for future 
research and government policy making on cost of antacids and anti-ulcer medica-
tions. Methods: Build a foundation based on drug DDD unit, analyze the index 
analysis system of the influence of drug mix of Cephalosporins on drug cost on 
different levels. Results: The total procurement costs of Cephalosporins for 
Guangdong province and the purchases of DDD increased by 158% and 120% respec-
tively in 2007-2011. At the same time, the price level declined significantly, the price 
index calculated by Laspeyres index decreased by 12%. ConClusions: The amount 
of drug utilization is the most important factor that caused cost increase, the 
decline of price inhibits the Cephalosporins drug price growth to a certain extent. 
Technological innovation is the motivating factor to cause the Cephalosporins drug 
price to increase.  There is a link between the level index of administration route 
and the rationality of drug use. The competition among different manufacturers is 
an important factor that affects the total expenditure of Cephalosporins.
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objeCtives: Infectious and parasitic diseases encompass some of the most deadly 
diseases including HIV, the sixth leading cause of death worldwide. The aim of this 
study was to investigate the similarities and differences between the approval of 
new drugs for the treatment of infectious and parasitic diseases in Japan and the 
USA. Methods: Drugs approved from 2004 to 2013 were identified through publi-
cally available reports on the USA Food and Drug Administration (FDA) and the 
Japanese Pharmaceuticals and Medical Devices Agency (PMDA) websites. Relevant 
drugs were defined as related to the treatment of infectious and parasitic diseases, 
according to the World Health Organisation International Classification of Diseases 
Version 2010. Results: The FDA and PMDA approved similar numbers of drugs 
indicated for infectious and parasitic diseases at 31 and 33 drugs, respectively. 
Eight HIV drugs were approved by each organisation, of which 5 were approved 
by both; each of these drugs was approved by the PMDA in the same or following 
year after FDA approval. With the exception of HIV and malarial drugs, the indi-
cations of drugs varied considerably between the FDA and PMDA. Following HIV, 
the most common infectious and parasitic drug groups for the FDA were hepatitis 
(20%), mycoses (17%) and bacterial (13%) whereas the PMDA had high incidences of 
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pitalisation data from 2,074 patients with PD who were recruited into the PD 
MED trial from Nov 2000 to Dec 2009 and followed up for ten years. PD MED is a 
large-scale, “real-life” randomised controlled trial comparing the effectiveness and 
cost-effectiveness of PD medications. Patients’ demographic characteristics, dis-
ease severity, reasons and duration of hospitalisation were analysed. Reasons for 
hospitalisations were coded based on the International Classification of Disease 
(ICD-10). Results: Of 2,074 patients, at randomisation, median age was 72 years 
(IQR 66-77), mean duration with diagnosed PD was 2.8 years (median 2, IQR 1-3) and 
median Hoehn &Yahr score was 2 (IQR 1.5-2.5). Until Oct 2011, 29% (597/2074) of 
patients had a total of 941 hospitalisation records. Mean length of stay was 21days 
(median 9, IQR 3-24). Hospitalisation reasons were classified into 11 categories of 
PD related conditions and 15 PD unrelated categories. 64.1% of the hospitalisation 
records can be associated with PD. Main reasons for hospitalisation were: infec-
tions including pneumonia and urinary tract infection (18.4%), falls and fractures 
and other injuries (15.3%), cardiovascular and circulatory disorders (8.7%), central 
nervous system and disorders of sense organs (8.2%), gastrointestinal disorders 
(8.0%), and mental health disorders (6.9%). ConClusions: PD related conditions 
have a significant and broad ranging specialty impact on hospitalisation rates 
and associated health care costs are substantial. This paper provides economic 
justification for investing in interventions that manage infection and prevent 
falls in people with PD.
NeuRologIcal dIsoRdeRs – Patient-Reported outcomes & Patient Preference 
studies
PNd5
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objeCtives: Alzheimer’s disease (AD) is a chronic and progressive disease that 
is a significant burden on caregivers. Research indicates AD caregiver burden 
on health status; but there is limited research on caregiver burden in Japan. The 
objectives of this study were to examine Japan AD caregiver burden vs. Japan non-
caregivers and 5E.U. AD caregivers. Methods: Data were obtained from the 2012 
Japan (N= 30,000) National Health and Wellness Survey (NHWS) and 2013 5E.U. (UK, 
Germany, France, Italy, Spain; N= 62,000) NHWS, administered online to a representa-
tive adult sample (18+ years). Respondents reported on health status (SF-36v2), 
activity impairment, health care utilization in the past six months and caregiver 
responsibilities. Multivariable regressions, adjusting for demographics and health 
history variables to explore differences between Japan AD caregivers (n= 714) vs. 
Japan non-caregivers (n= 27,702) and 5E.U. AD caregivers (n= 1,239). Results: Japan 
AD caregivers were older and reported more depression symptoms than Japan non-
caregivers (p< 0.05). Japan AD vs. 5E.U. AD caregivers were older and more educated 
(p< 0.05). After adjustments, Japan AD caregivers had lower health status (p< 0.001), 
higher health care utilization, and greater activity impairment (p< 0.001) than Japan 
non-caregivers. Japan AD vs. 5E.U. AD caregivers had better mental (45.7 vs. 43.8, 
p< 0.001) and physical (51.0 vs. 50.0, p= 0.021) health status, marginally less activity 
impairment (24.5% vs. 27.1%, p= 0.070), but more health care provider visits (7.6 vs. 
5.4, p< 0.001) and hospitalizations (p< 0.001). Japan AD caregivers vs. 5E.U. caregivers 
were less likely to make treatment decisions and manage finances for AD relative 
(p< 0.001), were marginally less involved in helping with daily activities (transporta-
tion, meals, shopping, p= 0.054), but no difference was found on bathing/grooming 
involvement. ConClusions: Japan AD caregivers report more burden including 
more depression symptoms than Japan non-caregivers. Japan AD caregivers report 
greater health care utilization than 5E.U. AD caregivers, but report better health 
status, and less involvement in treatment and finance decisions.
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objeCtives: Multiple Sclerosis (MS) is a chronic disease which results in increasing 
disability over time. The Australian Multiple Sclerosis Longitudinal Study (AMSLS) 
is an ongoing study that collects information on around 3,100 volunteers with MS 
from all States and Territories in Australia. The WHO quality of life assessment 
instrument (WHOQOL-100) was collected as well as the following Patient Reported 
Outcome (PRO) measures; MS Self-Efficacy Scale, Perceived Stress Scale, Geriatric 
Depression Scale – short version (GDP-5), Social Support Scale, Therapeutic Self-Care 
Scale, and the Depression Anxiety and Stress Scale (DASS). In this analysis, we quan-
tified the difference in utility, stress, depression and social support needs between 
disease severities in subjects with MS. Methods: Data from the WHOQOL-100 
were collected in 2008. The utility score was calculated by mapping five questions 
from the WHOQOL-100 to the EQ-5D descriptive system as described by Al-Ruzzeh 
et al (2008). The UK TTO value set (utility weights) were applied to each of the lev-
els in each dimension. Disease severity was based on the self reported Disease 
Steps Scale. Results: A total sample of 2139 subjects provided evaluable data; 
a response rate of approximately 70%. Overall average QOL as measured by the 
WHOQOL-100 was 13.7 (95%CI: 13.5 to 13.8) out of a maximum value of 20, ranging 
from 11.8 (95%CI: 11.4 to 12.2) in severe disease to 15.2 (95%CI: 15.0 to 15.4) when 
mild. The utility score for all people with MS was 0.65 (95%CI: 0.64 to 0.67). The 
utility decreased with increasing disease severity with values of 0.80 (95%CI: 0.78 
to 0.81), 0.60 (95%CI: 0.58 to 0.61) and 0.42 (95%CI: 0.39 to 0.46) for mild, moderate 
and severe disease, respectively. The other instruments on the whole followed this 
trend. ConClusions: Higher disease severity in subjects with MS is associated 
with lower utility and QOL and worse outcomes in general.
outcomes, and study designs). Results: A review of the clinical efficacy of ivacaftor, 
its comparative clinical efficacy compared with dornase alfa, and a review of the 
cost-effectiveness of ivacaftor will help to inform decisions about the treatment of 
patients with CF. Four studies were presented as evidence of the benefit of ivacaftor 
in CF. Two pivotal trials STRIVE and ENVISION, one open label extension study, 
PERSIST, for patients in STRIVE and ENVISION and a final study in different patient 
group, DISCOVER, in patients who are homozygous for the F508del mutation. The 
percent predicted forced expiratory volume in 1 second (FEV1) was the primary 
outcome measure for the two phase III clinical trials. The review group noted the 
absence of long term efficacy data particularly in relation to the benefit of ivacaftor 
in maintaining percent predicted FEV1 and reducing pulmonary exacerbations and 
the resultant impact on survival rates. The analysis for this extrapolation is based on 
a number of prediction models that have been published. The disease progression 
model predicts that the median survival for a patient treated with ivacaftor will 
be 29.2 years longer as a consequence of taking the drug. ConClusions: Whilst 
ivacaftor may represent an innovation for the treatment of patients with cystic 
fibrosis there are significant uncertainties, including the absence of long term health 
outcome data.
NeuRologIcal dIsoRdeRs – cost studies
PNd2
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5-yeaR tReNd aNalysIs
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objeCtives: To determine the trend of drug utilization for Alzheimer’s disease 
during 2009 and 2013. Methods: Prescription data of outpatients with Alzheimer’s 
disease in 2009 – 2013 was extracted from the medical care database of the hospital. 
Quantities and costs of the prescribed drugs were examined using defined daily dose 
(DDD) for comparisons. Results: Number of patients was rather the same number 
every year ranging from 1,507 to 1,631 patients. For donepezil and memantine, 
number of DDD per year was increased every year ranging from 7.3–10.0 % to 1.6-
14.7% compared to the previous year, respectively. The increasing trends were not 
found in prescribing of rivastigmine, except for the dramatically increase (34.0%) 
in 2013. Galantamine was prescribed less in 2010 and 2013 accounted for -9.2 and 
-18.2%, respectively. Cost of drug use in Alzheimer’s disease was $3,211,269 in 2009 
and $3,228,454 in 2013 with an increasingly trend. ConClusions: The overall drug 
use in Alzheimer’s disease seems to be a heavy burden of the hospital every year. 
The rational drug use should be confirmed to make sure to guarantee appropriate 
use of drug without overusage.
PNd3
best PRactIces aNd Key cHalleNges IN cost-effectIveNess modellINg 
of multIPle scleRosIs tHeRaPIes
Smith N., Beckerman R.
CBPartners, New York, NY, USA
objeCtives: The purpose of this study was to review cost-effectiveness models in 
multiple sclerosis (MS) to identify accepted methods, key challenges, and best prac-
tices.  Methods: We searched MEDLINE, Embase, the Health Economics Evaluation 
Database (HEED), the Cochrane library, and recent HTA agencies’ (NICE and SMC) deci-
sions  for studies published prior to March 7, 2014. Following duplicate removal, 100 
studies were identified. Studies were excluded if they did not estimate cost-effective-
ness in MS, were duplicates, or weren’t published in English, resulting in a total of 26 
studies sourced. A data extraction form was developed to capture information about 
model characteristics, patient natural history progression, utility estimates, and the 
author’s comments on the modelling methods. Results: All studies were published 
after 2000, with most focused on first-line USA and EU patient populations. The major-
ity of models utilised a cohort Markov model approach, with health states defined by 
patient expanded disability status scale (EDSS) scores. Health states included either 
individual or aggregate EDSS scores (0-9.5) for relapsing-remitting MS (RRMS) and sec-
ondary progressive MS (SPMS), as well as a death state. Transition probabilities were 
sourced from trial data for low score EDSS states, while transitions for higher score 
EDSS states were sourced from a longitudinal study of Canadian MS patients, due 
to insufficient clinical trial data for patients with advanced disease. Key challenges 
identified in recent HTA decisions include modelling EDSS score improvement early 
in disease natural history, patients’ initial distributions across EDSS states, extended 
benefits of therapy, and patient treatment adherence. ConClusions: Established 
modelling best practice in MS utilises a cohort Markov model approach with health 
states simulating patient populations via EDSS scores in RRMS and SPMS. Future 
studies and HTA submissions should focus on more accurately reflecting patient 
natural history in the early stages of disease.
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objeCtives: Reasons for hospitalisations in people with Parkinson’s Disease 
(PD) are broad ranging and costly, however detailed analysis of hospitalisations 
in a large, representative group of PD patients is lacking. This study aimed to 
explore the reasons for, resource use and associated cost of hospital treatment 
in participants in the PD MED trial. Methods: We retrospectively reviewed hos-
